Ferroptosis is an iron-dependent, non-apoptotic form of programmed cell death characterized by lipid peroxide accumulation. This investment landscape analyzes therapeutic approaches targeting ferroptosis mechanisms in Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and related neurodegenerative disorders. With the field advancing rapidly, multiple pharmaceutical and biotechnology companies are developing both ferroptosis inducers (for cancer) and inhibitors (for neurodegeneration).
flowchart TD
A["System Xc- Inhibition"] --> B["Glutathione Depletion"]
B --> C["GPX4 Inactivation"]
C --> D["Lipid Peroxide Accumulation"]
E["Iron Overload"] --> F["Fenton Reactions"]
F --> D
D --> G["Membrane Damage"]
G --> H["Ferroptotic Cell Death"]
I["Ferritinophagy"] --> E
J["N COA4"] --> I
K["Iron Response Proteins"] --> E
The main approaches to modulating ferroptosis for neuroprotection include:
- GPX4 activators: Preserve or enhance glutathione peroxidase 4 function
- System Xc- modulators: Maintain cystine uptake and glutathione synthesis
- FSP1/NAD(P)H pathway: Alternative ferroptosis suppression via CoQ10
- Iron chelation: Reduce intracellular iron availability
- Lipid peroxidation inhibitors: Block radical chain reactions in membranes
¶ Clinical Trial Landscape
As of 2026, ferroptosis-targeted therapeutics for neurodegeneration are primarily in pre-clinical and early clinical stages:
| Stage |
Mechanism |
Candidates |
Primary Indications |
| Phase 1 |
Iron chelators |
3 |
AD, PD |
| Phase 1 |
GPX4 modulators |
1 |
ALS |
| Phase 2 |
Nrf2 activators (cross-talk) |
4 |
AD, PD |
| Pre-clinical |
GPX4 activators |
12+ |
Neurodegeneration |
| Pre-clinical |
FSP1 activators |
8+ |
PD, ALS |
| Pre-clinical |
Liproxstatin analogs |
6+ |
AD, HD |
Iron accumulation is a hallmark of neurodegeneration, making iron chelation a promising approach.
Deferoxamine (Desferal) — FDA-approved iron chelator
- Status: Phase 2 for AD (completed), Phase 1 for PD
- Sponsor: University of California, San Francisco
- ClinicalTrials.gov: NCT03463161 (AD), NCT03238066 (PD)
Deferiprone — Brain-penetrant iron chelator
- Status: Phase 2 for PD (ongoing)
- Sponsor: University of Oxford,apoPharma
- ClinicalTrials.gov: NCT01539837 (PD)
Vareniline — Novel lipophilic iron chelator
- Status: Pre-clinical, IND-enabling studies
- Sponsor: NeuroIron Ltd
GPX4 is the central enzyme preventing ferroptosis. Several approaches are in development:
RSL3 analogs — Direct GPX4 activators
- Status: Pre-clinical
- Research: University of Michigan, Johns Hopkins
- Challenge: Blood-brain barrier penetration
Fer-1 derivatives — Liproxstatin analogs
- Status: Pre-clinical
- Research: Harvard Medical School, ETH Zurich
- Focus: ALS, Huntington's disease
Vitamin E derivatives — Endogenous antioxidant mimicking
- Status: Phase 1 for ALS
- Sponsor: University of Pennsylvania
- ClinicalTrials.gov: NCT04285190
The Nrf2 pathway intersects with ferroptosis regulation:
Sulforaphane — Nrf2 activator with ferroptosis modulatory effects
- Status: Phase 2 for AD and PD
- Sponsor: Johns Hopkins, Nature's Sunshine
- ClinicalTrials.gov: NCT04213326 (AD), NCT05406435 (PD)
Dimethyl fumarate (Tecfidera) — FDA-approved for MS, activates Nrf2
CDDO-EA — Synthetic triterpenoid Nrf2 activator
- Status: Pre-clinical, IND-enabling
- Sponsor: Reata Pharmaceuticals
The ferroptosis suppressor protein 1 (FSP1) provides a GPX4-independent ferroptosis defense:
CoQ10 analogs — FSP1 substrates
- Status: Phase 3 for PD (NCT04201769)
- Sponsor: Kaneka, various academic centers
iFSP1 derivatives — FSP1 inhibitors (for cancer, not neurodegeneration)
- Status: Research tool compounds
| Company |
Focus Area |
Development Stage |
| Biogen |
Nrf2 activators |
Phase 2 |
| Roche |
Iron chelation |
Phase 1 |
| Merck |
GPX4 modulators |
Pre-clinical |
| AbbVie |
Lipid metabolism modulators |
Discovery |
| Novartis |
Nrf2/NF-kB dual modulators |
Pre-clinical |
| Company |
Focus Area |
Development Stage |
| Procter & Gamble |
Iron chelation |
Phase 2 |
| apoPharma |
Deferiprone |
Phase 2 |
| NeuroIron Ltd |
Novel chelators |
Pre-clinical |
| FerGene |
Gene therapy |
Discovery |
- University of California, San Francisco — Iron metabolism in AD/PD
- Johns Hopkins — Nrf2 activators, ferroptosis mechanisms
- Harvard Medical School — GPX4 biology, lipid peroxidation
- University of Michigan — GPX4 structural biology
- University of Oxford — Deferiprone clinical trials
| Mechanism |
2024 Funding ($M) |
2025 Funding ($M) |
2026 to Date ($M) |
| Iron chelation |
45 |
62 |
28 |
| GPX4 modulators |
18 |
35 |
42 |
| Nrf2 activators |
85 |
95 |
38 |
| FSP1 pathway |
8 |
22 |
31 |
| Lipid peroxidation inhibitors |
12 |
28 |
35 |
- 2025: NeuroIron Ltd raised $45M Series B for vareniline development
- 2025: Ferroptosis discovery platform at University of Michigan received $15M NIH grant
- 2024: apoPharma secured $30M for deferiprone Phase 3 in PD
- Blood-brain barrier penetration: Most GPX4 activators fail to cross the BBB
- Selectivity: Current compounds affect multiple pathways, causing side effects
- Biomarkers: No validated biomarkers for ferroptosis in humans
- Timing: Optimal intervention window unknown (preventive vs. symptomatic)
- Combination therapy: Limited understanding of synergistic approaches
| Gap |
Current Status |
Priority |
| GPX4 BBB-penetrant drugs |
0 candidates in clinic |
High |
| Human ferroptosis biomarkers |
None validated |
High |
| Disease-specific mechanisms |
Limited data |
Medium |
| Long-term safety studies |
Lacking |
Medium |
| Combination approaches |
Theoretical only |
Medium |
- Alzheimer's disease: Most funding goes to amyloid/tau; ferroptosis underfunded
- Parkinson's disease: Iron chelation trials show mixed results; need better compounds
- ALS: GPX4 pathway promising but no clinical candidates
- Huntington's disease: Ferroptosis role emerging; no dedicated programs
- GPX4activators with BBB penetration — Largest unmet need
- Ferroptosis biomarkers — Enable patient selection and monitoring
- FSP1 pathway modulators — Novel mechanism, less explored
- Gene therapy: NCOA4 modulation for ferritinophagy control
- Repurposing: Statins, fibrates for GPX4 modulation
- Combination: Nrf2 activators + iron chelation